8-K: Foghorn Therapeutics CFO Resigns, Q3 Net Loss Narrows

Foghorn Therapeutics announced its third-quarter 2025 financial results, reporting a narrowed net loss and pipeline progress, alongside the resignation of its Chief Financial Officer.

Summary

• Net loss for the three months ended September 30, 2025, was $15.8 million, an improvement from a net loss of $19.1 million for the same period in 2024.
• Collaboration revenue increased to $8.2 million for Q3 2025, up from $7.8 million for Q3 2024, driven by the Lilly Collaboration Agreement.
• Research and development expenses decreased to $20.0 million for Q3 2025, compared to $24.7 million for Q3 2024.
• General and administrative expenses were $6.7 million for Q3 2025, a decrease from $7.0 million for Q3 2024.
• Cash, cash equivalents, and marketable securities totaled $180.3 million as of September 30, 2025, providing a cash runway into 2028.
• Kristian Humer resigned as Chief Financial Officer, effective November 14, 2025, to pursue other opportunities.
• The Phase 1 dose escalation trial for FHD-909 (LY4050784) in SMARCA4-mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target, is on track and enrolling well.
• The Selective CBP degrader entered non-GLP toxicology studies in Q4 2025, with IND-ready anticipated in 2026, showing potential in EP300-mutant cancers and ER+ breast cancer.
• The Selective EP300 degrader demonstrates robust preclinical anti-tumor activity and favorable tolerability across hematological malignancies, with IND-enabling studies expected in 2026.
• The Selective ARID1B degrader is advancing towards in vivo proof of concept in 2026, with relevance in up to 5% of solid tumors.

Sentiment

Score: 7

Explanation: The filing presents a generally positive outlook with narrowed losses, increased revenue, and significant pipeline progress, supported by a strong cash position. The CFO resignation is a minor negative, but not attributed to financial issues.

Positives

• Net loss narrowed to $15.8 million in Q3 2025 from $19.1 million in Q3 2024, indicating improved financial performance.
• Collaboration revenue increased to $8.2 million in Q3 2025, up from $7.8 million in Q3 2024, driven by the Lilly Collaboration Agreement.
• Research and development expenses decreased to $20.0 million in Q3 2025 from $24.7 million in Q3 2024, reflecting cost management.
• General and administrative expenses decreased to $6.7 million in Q3 2025 from $7.0 million in Q3 2024.
• Strong balance sheet with $180.3 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
• Cash runway extended into 2028, providing significant financial stability for ongoing operations and pipeline development.
• FHD-909 Phase 1 trial is enrolling well and remains on track, with NSCLC as the primary target population.
• Preclinical data for FHD-909 shows synergistic anti-tumor activity in combination with standard-of-care chemotherapies, anti-PD-1 pembrolizumab, and KRAS inhibitors.
• Wholly-owned selective degrader programs (CBP, EP300, ARID1B) are advancing with positive preclinical data and clear next milestones.
• Selective CBP degrader shows no significant impact on platelet counts and spares megakaryocytes in preclinical studies, differentiating it from dual inhibitors.
• Selective EP300 degrader demonstrates broad anti-tumor activity in over 70% of heme sub-lineages tested and impressive efficacy in Multiple Myeloma without hematological toxicities.
• VHL-based selective EP300 degrader maintains activity in IMiD-resistant Multiple Myeloma cell lines.
• ARID1B degrader shows robust and selective degradation of the protein and demonstrated effects on downstream target genes.

Negatives

• Chief Financial Officer, Kristian Humer, is departing effective November 14, 2025, which could create a temporary leadership gap during the search for a replacement.
• The company continues to operate at a net loss, despite the narrowing of the loss.
• Cash, cash equivalents, and marketable securities decreased from $243.7 million at December 31, 2024, to $180.3 million at September 30, 2025.
• Total stockholders deficit increased from $(45.5) million at December 31, 2024, to $(89.7) million at September 30, 2025.

Risks

• Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, potentially causing actual results to differ materially.
• Risks relating to clinical trials, including the initiation, timing, progress, and results of research and development programs and preclinical studies.
• Regional, national, or global political, economic, business, competitive, market, and regulatory conditions.
• Ability to advance product candidates and successfully complete preclinical and clinical studies.
• Ability to leverage initial programs to develop additional product candidates using the Gene Traffic Control Platform.
• Impact of exogenous factors, including macroeconomic and geopolitical circumstances, on business operations.
• Developments related to competitors and the industry.
• Ability to expand the target populations of programs and the availability of patients for clinical testing.
• Ability to obtain regulatory approval for FHD-909 and any future product candidates from the FDA and other regulatory authorities.
• Ability to identify and enter into future license agreements and collaborations.
• Ability to continue to rely on CDMOs and CROs for manufacturing and research needs.
• Regulatory developments in the United States and foreign countries.
• Ability to attract and retain key scientific and management personnel.
• Scope of protection for intellectual property rights covering FHD-909, future products, and the Gene Traffic Control Platform.
• Use of proceeds from capital-raising transactions, estimates of expenses, capital requirements, and needs for additional financing.

Future Outlook

The company anticipates continued advancement of its oncology pipeline, including the ongoing Phase 1 trial for FHD-909, and expects its Selective CBP degrader to be IND-ready in 2026, with IND-enabling studies for its Selective EP300 degrader and in vivo proof of concept for its Selective ARID1B degrader also expected in 2026. The company projects its current cash, cash equivalents, and marketable securities will provide a runway into 2028.

Management Comments

• "This quarter marked continued execution across our portfolio, reinforcing our leadership in developing novel precision therapies with broad applicability across cancers." Adrian Gottschalk, President and Chief Executive Officer.
• "FHD-909, in collaboration with Lilly, is advancing in a Phase 1 dose escalation trial for the treatment of SMARCA4-mutated cancers with a focus on NSCLC. Based on our preclinical monotherapy and combination data, we are enthusiastic about the development of FHD-909 with the goal of developing it as a front-line therapy in NSCLC." Adrian Gottschalk, President and Chief Executive Officer.
• "Our strategic collaboration with Lilly provides the necessary strategic and financial resources to develop FHD-909." Adrian Gottschalk, President and Chief Executive Officer.
• "Momentum is strong for our wholly-owned, first-in-class selective degrader programs targeting CBP, EP300 and ARID1B with program updates highlighted during our recent virtual investor event." Adrian Gottschalk, President and Chief Executive Officer.
• "Backed by our strong balance sheet and a cash runway into 2028, we are focused on delivering breakthrough therapies that harness the broad therapeutic potential of protein degradation and chromatin regulation." Adrian Gottschalk, President and Chief Executive Officer.
• "Finally, I want to thank Kristian for his leadership and commitment during his time at Foghorn. He has been a valued member of the team, and I wish him well in his future endeavors." Adrian Gottschalk, President and Chief Executive Officer.

Industry Context

Foghorn Therapeutics operates in the highly competitive and innovative biotechnology sector, specifically focusing on oncology through chromatin regulatory system modulation and protein degradation. The advancement of its pipeline, particularly in SMARCA4-mutated NSCLC and other solid tumors, positions it within a growing segment of precision oncology. The strategic collaboration with Lilly provides significant validation and resources, aligning with a broader industry trend of larger pharmaceutical companies partnering with specialized biotech firms to access novel therapeutic platforms and accelerate drug development for challenging targets like CBP, EP300, and ARID1B, which have historically been difficult to drug selectively.

Comparison to Industry Standards

• The company's focus on SMARCA4-mutated NSCLC with FHD-909 addresses a high unmet need population with poor prognosis and less responsiveness to immune checkpoint inhibitors, differentiating it from standard-of-care treatments like pembrolizumab-based regimens, chemotherapy, and KRAS inhibitors, which FHD-909 aims to combine with.
• The selective CBP and EP300 degrader programs aim to overcome dose-limiting toxicities associated with dual CBP/EP300 inhibition, a known challenge in the field, by achieving high selectivity. This contrasts with dual inhibitors like CCS1477 (Inobrodib), which has shown limitations due to thrombocytopenia.
• The ARID1B degrader program targets a "previously undruggable" large, unstructured protein with no known enzymatic function, representing a significant challenge that, if successful, would set a new benchmark in targeting such proteins.
• The cash runway into 2028 is a strong position for a clinical-stage biotech, providing stability for ongoing R&D compared to many peers who may face more immediate financing pressures.

Management Changes

Stakeholder Impact

• Shareholders: Potential positive impact from pipeline progress, extended cash runway, and narrowed net loss. CFO departure could introduce short-term uncertainty.
• Employees: Search for a new CFO may impact the finance department. Continued R&D progress suggests stability and potential growth opportunities.
• Customers (future patients): Continued progress in oncology pipeline offers hope for new treatment options for various cancers, including SMARCA4-mutated NSCLC, EP300-mutant cancers, ER+ breast cancer, hematological malignancies, and ARID1A-mutant solid tumors.
• Partners (Lilly): Collaboration appears to be progressing well, with FHD-909 advancing in clinical trials.
• Creditors/Suppliers: Strong cash position and extended runway indicate good financial health for meeting obligations.

Next Steps

• Continue enrollment in the Phase 1 multi-center trial of FHD-909.
• Further development plans for FHD-909 based on combination preclinical data.
• Advance Selective CBP degrader towards IND-ready status in 2026.
• Advance Selective EP300 degrader towards IND-enabling studies in 2026.
• Advance Selective ARID1B degrader towards in vivo proof of concept in 2026.
• Conduct a formal search for a successor to the Chief Financial Officer.
• Perform LAI characterization in additional pharmacology studies to refine human dose predictions for CBPd-171.

Key Dates

Recommendation

The company demonstrated solid progress in its clinical pipeline and improved financial metrics with a narrowed net loss and extended cash runway. The strategic collaboration with Lilly continues to advance, and wholly-owned programs show promising preclinical data. However, the resignation of the CFO introduces a degree of uncertainty, and the company remains in a net loss position. While the long-term potential is significant, particularly with its innovative approach to chromatin biology, the stock is a 'hold' as investors await further clinical data and the appointment of a new CFO to fully assess the company's trajectory and mitigate short-term leadership transition risks.

Keywords

Foghorn Therapeutics, FHTX, Biotechnology, Oncology, SMARCA4-mutated cancer, NSCLC, FHD-909, LY4050784, CBP degrader, EP300 degrader, ARID1B degrader, Protein degradation, Chromatin regulation, Clinical trial, Financial results, Q3 2025, Net loss, Cash runway, CFO resignation, Lilly collaboration, Precision medicine, Gene Traffic Control platform